Trial Profile
Effects of high- versus standard-dose olmesartan medoxomil on plasma levels of inflammatory markers and aldosterone in patients with essential hypertension
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 May 2012
Price :
$35
*
At a glance
- Drugs Olmesartan medoxomil (Primary)
- Indications Essential hypertension
- Focus Biomarker; Pharmacodynamics
- 13 May 2012 New trial record
- 29 Apr 2012 Results presented at the 22nd European Meeting on Hypertension.